LCTX — Lineage Cell Therapeutics Cashflow Statement
0.000.00%
Last trade - 00:00
- $216.81m
- $180.07m
- $8.95m
2019 December 31st | 2020 December 31st | 2021 December 31st | 2022 December 31st | 2023 December 31st | |
---|---|---|---|---|---|
Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
Source: | 10-K | 10-K | 10-K | 10-K | 10-K |
Standards: | USG | USG | USG | USG | USG |
Status: | Final | Final | Final | Final | Final |
Net Income/Starting Line | -11.7 | -20.6 | -43 | -26.3 | -21.5 |
Depreciation | |||||
Amortisation | |||||
Deferred Taxes | |||||
Non-Cash Items | -21.5 | -2.52 | -2.51 | 7.9 | 4.83 |
Unusual Items | |||||
Equity in Net Earnings/Losses | |||||
Other Non-Cash Items | |||||
Changes in Working Capital | -1.9 | 1.3 | 21.1 | 18.7 | -10.8 |
Change in Accounts Receivable | |||||
Change in Prepaid Expenses | |||||
Change in Accrued Expenses | |||||
Change in Payable / Accrued Expenses | |||||
Change in Other Liabilities | |||||
Other Operating Cash Flow | |||||
Cash from Operating Activities | -31.9 | -19.8 | -23.6 | 1.06 | -28.6 |
Capital Expenditures | -0.44 | -0.064 | -0.354 | -0.413 | -0.674 |
Purchase of Fixed Assets | |||||
Other Investing Cash Flow Items | 17.4 | 13.1 | 10.1 | -45.7 | 47.1 |
Sale of Business | |||||
Sale of Fixed Assets | |||||
Sale/Maturity of Investment | |||||
Purchase of Investments | |||||
Other Investing Cash Flow | |||||
Cash from Investing Activities | 17 | 13 | 9.74 | -46.2 | 46.4 |
Financing Cash Flow Items | 0.654 | -0.383 | -1.16 | -0.123 | -0.236 |
Other Financing Cash Flow | |||||
Net Issuance / Retirement of Stock | |||||
Net Issuance / Retirement of Debt | |||||
Cash from Financing Activities | 0.617 | 29.9 | 36.9 | 1.63 | 6.42 |
Foreign Exchange Effects | |||||
Beginning Cash Balance | |||||
Ending Cash Balance | |||||
Net Change in Cash | -14.3 | 23.1 | 23.1 | -44.3 | 24.1 |